- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 2 - Genetics and Next-Generation Sequencing
Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.
Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.
Dr Chernew questions the value of circulating plasma cells as independent prognostic markers in newly diagnosed multiple myeloma, as well as circulating serum microRNAs for diagnosis of multiple myeloma.
The panelists then discuss next-generation sequencing, deep sequencing, and ASO-qPCR in detecting minimal residual disease (MRD). Dr Kumar says there is a growing interest in MRD and explains all the emerging developments for detection of MRD.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
